- Home
- CALX vs PTGX Comparison
CALX vs PTGX Comparison
Compare CALX & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALX
- PTGX
- Stock Information
- Founded
- CALX 1999
- PTGX 2006
- Country
- CALX United States
- PTGX United States
- Employees
- CALX N/A
- PTGX N/A
- Industry
- CALX Telecommunications Equipment
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- CALX Consumer Discretionary
- PTGX Health Care
- Exchange
- CALX Nasdaq
- PTGX Nasdaq
- Market Cap
- CALX 2.4B
- PTGX 2.8B
- IPO Year
- CALX 2010
- PTGX 2016
- Fundamental
- Price
- CALX $37.11
- PTGX $47.91
- Analyst Decision
- CALX Strong Buy
- PTGX Strong Buy
- Analyst Count
- CALX 6
- PTGX 7
- Target Price
- CALX $42.50
- PTGX $52.83
- AVG Volume (30 Days)
- CALX 368.7K
- PTGX 450.1K
- Earning Date
- CALX 10-28-2024
- PTGX 11-08-2024
- Dividend Yield
- CALX N/A
- PTGX N/A
- EPS Growth
- CALX N/A
- PTGX N/A
- EPS
- CALX N/A
- PTGX 2.75
- Revenue
- CALX $890,128,000.00
- PTGX $319,120,000.00
- Revenue This Year
- CALX N/A
- PTGX $400.33
- Revenue Next Year
- CALX $4.01
- PTGX N/A
- P/E Ratio
- CALX N/A
- PTGX $17.54
- Revenue Growth
- CALX N/A
- PTGX 125.73
- 52 Week Low
- CALX $26.76
- PTGX $13.76
- 52 Week High
- CALX $45.15
- PTGX $48.89
- Technical
- Relative Strength Index (RSI)
- CALX 50.00
- PTGX 60.40
- Support Level
- CALX $36.89
- PTGX $45.33
- Resistance Level
- CALX $40.41
- PTGX $48.89
- Average True Range (ATR)
- CALX 1.16
- PTGX 1.28
- MACD
- CALX -0.08
- PTGX 0.11
- Stochastic Oscillator
- CALX 34.89
- PTGX 77.11
About CALX Calix Inc
Calix Inc develops, market and sell Calix cloud, systems and software platforms to enable service providers of all types and sizes to innovate and transform. The company's customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates more value for their businesses and communities. The Company's revenue is principally derived in the United States and it also has its presence in Middle East & Africa, Europe, Asia Pacific and other markets.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.